Company Announcement no. 03/2008 To: OMX Nordic Exchange Copenhagen Hørsholm, Denmark, January 31, 2008 LifeCycle Pharma's Financial Calendar 2008 Hørsholm, Denmark, January 31, 2008; LifeCycle Pharma A/S (OMX: LCP), an emerging specialty pharmaceuticals company, hereby issue its Financial Calendar 2008: -------------------------------------------------------------------------------- | Date | Event | -------------------------------------------------------------------------------- | 28 February 2008 | Financial Statements for the Full Year 2007 | -------------------------------------------------------------------------------- | 7 April 2008 | Publication of Annual Report 2007 | -------------------------------------------------------------------------------- | 24 April 2008 | Annual General Meeting | -------------------------------------------------------------------------------- | 14 May 2008 | Interim Financial Statements for the period ending 31 | | | March 2008 | -------------------------------------------------------------------------------- | 27 August 2008 | Interim Financial Statements for the period ending 30 | | | June 2008 | -------------------------------------------------------------------------------- | 26 November 2008 | Interim Financial Statements for the period ending 30 | | | September 2008 | -------------------------------------------------------------------------------- About LifeCycle Pharma A/S (“LCP”) LCP is an emerging specialty pharmaceuticals company that, through innovative technologies, is able to rapidly develop a portfolio of differentiated products to meet the unique needs of key therapeutic markets and patient populations. This includes products for immunosuppression, specifically organ transplantation, and to combat certain cardiovascular diseases. By using its unique and patented delivery technology, MeltDose®, LCP is able to develop drugs with enhanced absorption and thereby increased bioavailability. Currently, the Company has a diversified near- and medium-term pipeline, including a product ready for US commercialization, five product candidates in clinical trials and three in preclinical stages of development. LCP is listed on the OMX Nordic Exchange under the trading symbol (OMX: LCP). For further information, please visit www.lcpharma.com. For further information please contact LifeCycle Pharma A/S: -------------------------------------------------------------------------------- | Flemming Ornskov, MD | | | President and CEO | | | +45 2420 0368; FO@lcpharma.com | | --------------------------------------------------------------------------------